Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | DTYMK | P23919 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055955 | 0.91 | POLB (0.47) | POLBOPRD1OPRK1GPR119DTYMK | |
| SCHEMBL2899666 | 0.89 | POLB (0.47) | POLBOPRD1OPRK1GPR119DTYMK | |
| SCHEMBL3249336 | 0.83 | POLB (0.52) | POLBOPRD1OPRK1GPR119DTYMK | |
| SCHEMBL3562470 | 0.83 | OPRL1 (0.42) | POLBOPRD1OPRK1 | |
| SCHEMBL3325436 | 0.83 | GPR119 (0.50) | POLBOPRD1OPRK1GPR119DTYMK | |
| SCHEMBL5479635 | 0.82 | POLB (0.51) | POLBOPRD1OPRK1GPR119DTYMK | |
| SCHEMBL3557560 | 0.81 | POLB (0.47) | POLBOPRD1OPRK1GPR119DTYMK | |
| SCHEMBL22495695 | 0.80 | POLB (0.47) | POLBOPRD1OPRK1GPR119DTYMK | |
| SCHEMBL3555626 | 0.80 | POLB (0.48) | POLBOPRD1OPRK1GPR119DTYMK | |
| SCHEMBL22792894 | 0.80 | POLB (0.48) | POLBOPRD1OPRK1GPR119DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1729772-B1 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1729772-B1 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2016-12-07 | — | — | EP | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| EP-1729772-A4 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| EP-1729772-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck and Co., Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094514-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005094514-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | POLB 3743/4885OPRD1 462/4885OPRK1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.